Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        It’s time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic        Fruits, Veggies May Help Smokers Quit     

Member Sign In
Forgot Your
Username & Password?

Not a Member?
Please Sign Up Here

Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

Beximco Pharmaceuticals Ltd
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is the largest exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and currently producing more than 400 products in different dosage forms covering broader therapeutic categories which include antibiotics, antihypertensives, antidiabetics, antireretrovirals, anti asthma inhalers etc, among many others.

The company was incorporated in 1976 and commenced operations in 1980 with the manufacturing and marketing of products of Bayer AG, Germany and Upjohn Inc., USA under licensing arrangements.

In 1983, the company started manufacturing its own formulations and it launched export operation in 1992.

In 2005 Beximco Infusions Ltd, the company that produces intravenous fluids, was amalgamated with the parent company. In the same year it completed the state-of-the-art oral solid dosage plant in compliance with the US FDA and UK MHRA standards, which has been approved by major global regulatory bodies.

Today Beximco Pharma is the largest exporter of pharmaceuticals in the country and the only company to win National Export Trophy (Gold), the highest national accolade for export, for record three times.

The company is the largest producer of Metered Dose Inhalers (MDIs) in the country, and the first to produce CFC free inhalers. BPL is also the first company to produce anti-retroviral drugs (ARVs) locally
Manufacturing Facilities
Located at Tongi, near the capital city Dhaka, BPL s manufacturing site is spread over an area of 20 acres which houses a number of self contained production units including oral solids, metered dose inhalers, intravenous fluids, liquids, ointments, creams, suppositories, ophthalmic drops, injectables, nebulizer solutions etc. The bulk drug unit for producing paracetamol is also located within this site. Company s penicillin API and formulation units are situated at Kaliakoir, a few kms from the main site.

The plant and machinery throughout the site have been designed by and procured mostly from renowned European companies.

Beximco Pharma has its own utility infrastructure to ensure adequate generation and distribution of purified water at all times. The installed capacity of power generation is 8 MW. There is also liquid nitrogen generation facility on site.
Oral Solid Dosage (OSD) Plant
Beximco Pharma has invested over US $ 50 million on this new Oral Solid Dosage (OSD) plant complying with guidelines of highly regulated markets (for example, USFDA, UKMHRA, TGA Australia etc.). This state-of-the-art facility incorporates modern technological advancements.

The building finishes have been made to comply with our design standards which have been prepared with the global standards (e.g. non shedding materials, resistant to cleaning agents, flush fitting etc.). Same is the case for HVAC system which has been installed to meet the global standards for air classification, air changes etc.

The manufacturing and packaging facilities have been designed to minimize generation and maximize containment of dust particles using closed transfer system and clean in place facility. All practicable measures have been taken to ensure that members of the staff are not exposed to unacceptable concentrations of dust particles. Process area, cubicles, storage area have been connected to vacuum dust cleaning. The design of the plant ensures automated materials handling systems and multilevel designs to enable gravity feed between processing stages. The building design has also allowed maximum engineering maintenance access without entering into the production areas.

Precise selection of equipment is also critical to improve process capability and ensure process robustness. A wide range of equipment has been procured from world renowned companies like Glatt, Romaco, Noack, Korsch and Nicomac.

A state-of-the-art chemical laboratory and dedicated microbiological laboratory equipped with a wide range of equipment have been set up to facilitate the quality control activities. The major equipment include HPLCs, UV spectrophotometer, FTIR spectrophotometer, AA Spectrophotometer, Karl Fischer titrator etc.

This plant provides greater capacity and a strong platform to launch Beximco Pharmas products into highly regulated developed markets including Europe and the USA.
State of the art MDI Plant
The Metered Dose Inhaler (MDI) manufacturing plant of Beximco Pharma is one of the finest facilities in the world to produce Ozone benign HFA based MDI products. The plant was designed and installed under the technical collaboration of Pamasol, Switzerland.

The facility has dedicated areas for dispensing, manufacturing, canister and valve cleaning, canister filling, quarantine storage area, spray testing, packaging, propellant storage and in process control. As the inhaler manufacturing operation requires stringent control of humidity and temperature, automatic monitoring equipment are in use to continuously record temperature and relative humidity in areas like dispensing room, suspension manufacturing room, filling room, quarantine room etc.

The manufacturing equipment like manufacturing vessel, filling machine, weight checker, spray checking have been procured from Pamasol, Switzerland, a world renowned equipment supplier for Inhaler product manufacturing. The state-of-the-art Quality Control laboratory has been equipped with equipment like HPLC, Karl Fischer Titrator, Andersen Cascade Impactor etc.

MDI facility is the only approved outsourced facility of GlaxoSmithKline for their Ventolin® inhaler.

Due to the potential risk to the environment posed by CFCs, the technology shift in MDI industry is currently towards using hydrofluoroalkane (HFA) as propellants. Considering this changing trend in pulmonary drug delivery technologies, the company has aready developed the HFA based MDIs which inevitably requires very high level of expertise and sophisticated technology. We are among the very few companies in the world manufactuing CFC-free HFA MDIs.

Now with this state-of-the-art MDI facility, the company aims at obtaining marketing approvals from stringent regulatory authorities of the developed markets.
IV Fluid Manufacturing Plant
Beximco Pharma s intravenous (IV) fluid manufacturing plant may be regarded as one of the most technologically advanced plants in the world. The plant was designed and installed in collaboration with Pharmaplan of Germany, a sister concern of Fresenius AG of Germany.

In designing the whole process, special care has been taken by providing absolute sterile manufacturing conditions. The prime feature of the process is that there is no human physical contact with the product at any given time. This has been ensured by way of a series of fully automated manufacturing procedures including robotics. The bottle pack aseptic system (Form-Fill-Seal or FFS) is a unique and innovative manufacturing technology. Plastic bottles are blow moulded, filled with the solution and sealed under sterile conditions, in a single working cycle where there is no environmental exposure or human contact during manufacturing. The IV fluids are presented in a scientifically designed bottle where there is an extra protective eurohead cap and a resealable rubber disk. The whole process is performed in a class 100 clean room. The air inside this room is cleaned upto 100 particles per cubic feet passing it through HEPA (High Efficiency Particulate Air) filters.

Thus, an advanced sterile environment is maintained in manufacturing the IV fluids in order to avoid the entry of bacteria, pyrogen and inert particles into products. This ensures the highest standards of quality and purity in order to ensure the highest level of safety.

The plant is ISO 9001: 2000 certified.
Regulatory Approvals
The manufacturing facilities of Beximco Pharma have been audited and approved by:
  • National Health Surveillance Agency (ANVISA), Brazil (MDI)
  • Therapeutic Goods Administration (TGA), Australia (OSD, MDI and Spray)
  • Gulf Central Committee for Drug Registration (for GCC member states)(OSD & MDI)
  • Qualified by UNICEF (MDI & OSD)
  • Qualified by Global GlaxoSmithKline (MDI)
  • Qualified by Asthma Drug Facility (ADF), France (MDI)
  • Qualified by Global F Hoff Mann La Roche (OSD)
** Approvals by UK MHRA and USFDA are under process
Career at Beximco Pharmaceuticals Ltd.
  • Accounts & Finance
  • Central Product Management (Marketing)
  • Medical Services Officers
  • Human Resources & Admin
  • Supply Chain Management & Purchase
  • Sales & Product Promotion
  • Production
  • QA / QC
  • Engineering
Overseas Markets
The company is the largest exporter of pharmaceuticals from Bangladesh and the only company to receive National Export Trophy (Gold), the highest national accolade for export, for record three times. BPL has a global footprint in more than 45 countries across four continents and currently in the process of entering the emerging markets of CIS with increasing focus on regulated markets like EU and USA.

Besides the retail outlets, Beximco Pharmas products are being supplied to renowned hospitals and institutions like Raffles Hospital and K K Women & Children Hospital in Singapore, MEDS and Kenyatta National Hospital (KNH) in Kenya, Jinnah Hospital, and Agha Khan Hospital in Pakistan.

Beximco Pharmaceuticals Ltd.
19 Dhanmondi R/A, Road No. 7
Dhaka 1205, Bangladesh.
Telephone: +880-2-8619 151 (5 lines)
Fax: +880-2-8613 888 and +880-2-9663 579
Other Company or Institute Profile
United Hospital Ltd.
RAK Pharmaceuticals Pvt. Ltd.
Radiant Pharmaceuticals Limited
Drug International Ltd.
Eskayef Bangladesh Limited
Beximco Pharmaceuticals Ltd
Incepta Pharmaceuticals Ltd.
International Centre for Diarrhoeal Disease Research
See all the Comapany or Institute